David Planchard, Thoracic Oncologist, Professor at the University Paris Saclay and Head of the Thoracic Cancer Group at the Gustave Roussy, shared a post on X:
“Excellent session on HER2 (mut and overexpression) in lung cancer and ADCs with my Chinese colleagues…
T-DXd a game-changer for our pts! We must better understand resistance mechanisms and the best therapeutic sequencing with chemo-ICI /TKIs… and best first-line therapy?”
Could Proton Pump Inhibitors Affect Durvalumab Outcomes After Chemoradiotherapy in Stage III NSCLC?
